NDC-11 (Package) | NDC-9 (Product) (Descending) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00085-1366-05 | 00085-1366 | Temozolomide | Temodar | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 2, 2012 | In Use | |
00085-1312-01 | 00085-1312 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Jan. 13, 2016 | No Longer Used | ||
00085-1312-02 | 00085-1312 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Nov. 20, 2013 | No Longer Used | ||
00085-1287-02 | 00085-1287 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Jan. 13, 2016 | No Longer Used | ||
00085-1287-03 | 00085-1287 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Jan. 13, 2016 | No Longer Used | ||
00085-1254-01 | 00085-1254 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | Dec. 12, 2010 | No Longer Used | ||
00085-1242-01 | 00085-1242 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | Dec. 4, 2010 | No Longer Used | ||
00085-1235-01 | 00085-1235 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | Oct. 3, 2010 | No Longer Used | ||
00085-1168-01 | 00085-1168 | Interferon alfa-2b | Intron A | 11.6 ug/.5mL | Immunotherapy | Cytokine | Interferon | Intramuscular, Subcutaneous | June 4, 1986 | In Use | |
00085-1133-01 | 00085-1133 | Interferon alfa-2b | Intron A | 19.2 ug/.5mL | Immunotherapy | Cytokine | Interferon | Intralesional, Intramuscular, Subcutaneous | June 4, 1986 | In Use | |
00085-1110-01 | 00085-1110 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | July 31, 2016 | No Longer Used | ||
00085-0571-02 | 00085-0571 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | July 31, 2016 | No Longer Used | ||
00085-0539-01 | 00085-0539 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | July 31, 2016 | No Longer Used | ||
00085-0381-01 | 00085-0381 | Temozolomide | Temodar | Chemotherapy | Alkylating Agent | Tetrazine | Intravenous | Feb. 27, 2010 | March 18, 2010 | No Longer Used | |
00078-9342-61 | 00078-9342 | Octreotide Acetate | Sandostatin LAR Depot Demonstration Kit | Hormonal Therapy | Somatostatin Analog | Nov. 1, 1988 | Aug. 31, 2017 | No Longer Used | |||
00078-1161-47 | 00078-1161 | Trametinib | Mekinist | 0.05 mg/mL | Chemotherapy | MEK Inhibitor | BRAF | Oral | March 16, 2023 | In Use | |
00078-1154-21 | 00078-1154 | Dabrafenib | Tafinlar | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | March 16, 2023 | In Use | |
00078-1098-20 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1098-30 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1098-94 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1091-20 | 00078-1091 | asciminib | SCEMBLIX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1091-94 | 00078-1091 | asciminib | SCEMBLIX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-0958-19 | 00078-0958 | tisagenlecleucel | KYMRIAH | 60000000.0 1/1 | Immunotherapy | CAR-T | CD19 | Intravenous | May 1, 2018 | In Use | |
00078-0923-61 | 00078-0923 | letrozole and ribociclib | Kisqali Femara Co-pack | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 + Hormonal | Oral | May 4, 2017 | In Use | ||
00078-0916-61 | 00078-0916 | letrozole and ribociclib | Kisqali Femara Co-pack | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 + Hormonal | Oral | May 4, 2017 | In Use | ||
00078-0909-61 | 00078-0909 | Ribociclib and letrozole | Kisqali Femara Co-pack | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 + Hormonal | Oral | May 4, 2017 | In Use | ||
00078-0874-21 | 00078-0874 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
00078-0874-63 | 00078-0874 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
00078-0867-14 | 00078-0867 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
00078-0867-42 | 00078-0867 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
00078-0860-01 | 00078-0860 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 13, 2017 | In Use | |
00078-0846-19 | 00078-0846 | Tisagenlecleucel | Kymriah | 2000000.0 1/1 | Immunotherapy | CAR-T | CD19 | Intravenous | Aug. 30, 2017 | In Use | |
00078-0825-81 | 00078-0825 | Octreotide Acetate | Sandostatin LAR Depot | Hormonal Therapy | Somatostatin Analog | July 22, 2016 | In Use | ||||
00078-0818-81 | 00078-0818 | Octreotide Acetate | Sandostatin LAR Depot | Hormonal Therapy | Somatostatin Analog | July 22, 2016 | In Use | ||||
00078-0811-81 | 00078-0811 | Octreotide Acetate | Sandostatin LAR Depot | Hormonal Therapy | Somatostatin Analog | July 22, 2016 | In Use | ||||
00078-0716-56 | 00078-0716 | Capmatinib | TABRECTA | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | May 6, 2020 | In Use | |
00078-0716-94 | 00078-0716 | Capmatinib | TABRECTA | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | May 6, 2020 | In Use | |
00078-0715-02 | 00078-0715 | Alpelisib | PIQRAY | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | ||
00078-0715-91 | 00078-0715 | Alpelisib | PIQRAY | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | ||
00078-0709-56 | 00078-0709 | Capmatinib | TABRECTA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | May 6, 2020 | In Use | |
00078-0709-94 | 00078-0709 | Capmatinib | TABRECTA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | May 6, 2020 | In Use | |
00078-0708-02 | 00078-0708 | Alpelisib | PIQRAY | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | |
00078-0708-91 | 00078-0708 | Alpelisib | PIQRAY | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | |
00078-0701-84 | 00078-0701 | Alpelisib | PIQRAY | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | |
00078-0698-02 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0698-19 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0698-51 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0698-99 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0694-48 | 00078-0694 | ceritinib | ZYKADIA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | March 18, 2019 | In Use | |
00078-0694-84 | 00078-0694 | ceritinib | ZYKADIA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | March 18, 2019 | In Use |
Found 10,000 results in 6 milliseconds — Export these results